Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study

20250 citationsJournal Articlegold Open Access

Authors

Bradley E. Chipps · Capital Allergy and Respiratory Disease Center

Warner W. Carr

Reynold A. Panettieri · Rutgers, The State University of New Jersey

Weily Soong

Jennifer Trevor · University of Alabama at Birmingham

Andrew Lindsley · Amgen (United States)

Christopher S. Ambrose · AstraZeneca (Italy)

Abstract

Among this cohort of US subspecialist-treated adults with severe asthma and clinically relevant allergy, biologics decreased the rates of exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations, regardless of biologic subgroup.

Topics & Keywords

Asthma and respiratory diseases Allergic Rhinitis and Sensitization Dermatology and Skin Diseases

Publication Details

Published in: Journal of Allergy and Clinical Immunology Global

Volume 5, Issue 1, pp. 100590-100590

DOI: 10.1016/j.jacig.2025.100590

Field-Weighted Citation Impact: 0.00

Command Palette

Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study

Authors

Abstract

Topics & Keywords

Publication Details